NP 10679
Alternative Names: NP-10679Latest Information Update: 16 Jun 2025
At a glance
- Originator NeurOp
- Class Analgesics; Antiepileptic drugs; Neuroprotectants; Small molecules
- Mechanism of Action NR2B N-Methyl-D-Aspartate antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Pain; Subarachnoid haemorrhage
- Preclinical Stroke
- Research Depressive disorders
- Discontinued Epilepsy
Most Recent Events
- 05 Jun 2025 Seyltx enters into option agreement with NeurOp to in-license NP 10679
- 11 Jul 2024 Phase I clinical development is ongoing in Pain (In volunteers) in USA (IV, Infusion) (NeurOp website, July 2024)
- 11 Jul 2024 Phase I clinical development is ongoing in Subarachnoid-haemorrhage(In volunteers) in USA (IV, Infusion) (NeurOp website, July 2024)